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ABSTRACT 
Objective: Glycogen synthase kinase-3 beta (GSK-3β) plays a crucial role in several human diseases. GSK-3β is being one of the most attractive 
therapeutic targets for several decades across the research communities to discover new potent and selective inhibitors of GSK-3β. The objective of 
the research is to develop new compounds based on the QSAR and molecular docking studies. 
Methods: 2D/3D QSAR studies were conducted on a series of 5-substituted Indazole derivatives in order to optimize the GSK-3β inhibitors. 
Optimized inhibitors were subjected to molecular docking studies to find best inhibitors towards GSK-3β. 
Results: The significant QSAR model-3 (2D) and model-6 (3D) elucidate that T_C_N_5, T_2_N_0, SlogP, electrostatic potential (E_451, E_229) and 
hydrophobicity (H_1052) are important descriptors to conclude the biological activities of compounds. Docking study illustrates Val135, Gln185, 
Arg141 and Asp200 were essential interacting residues in the active site of the receptor with ligands. Based on QSAR models, 450 compounds were 
optimized and validated through docking studies. 
Conclusion: The best 31 optimized compounds, which showed good interaction energy, docking score and preferred interactions were selected as 
GSK-3β inhibitors. 
Keywords: Glycogen synthase kinase-3 Beta, GSK-3β, QSAR, Docking, Indazole. 
 
INTRODUCTION 
Glycogen synthase kinase-3 (GSK-3) is a multifunctional 
serine/threonine kinase and exists with two isoforms GSK-3α and 
GSK-3β in mammals with nearly 98% of identity but functionally not 
identical [4, 16], it is also known as human tau protein kinase (TPK 
I) [3]. Predominantly, various proteins are regulated through GSK-
3β and involved in neuronal growth, metabolic homeostasis [10] and 
inflammation [15]. Because of the distinctive roles of GSK-3β in 
pathophysiological, it is considered as a potential therapeutic target 
for the treatment of diabetes [9], Alzheimer’s disease [6], Mood 
disorders [7]. In addition to that GSK-3β is a pluripotent kinase [12] 
involved in cell functions and also reported its role in cancers such 
as Lung, Breast, colon, ovarian [5, 11, 9]. GSK-3β is also a potential 
therapeutic target for cancer [8]. As the inhibition of GSK-3β is a 
prospective approach to treat various diseases conditions, it gets 
more attention in drug discovery industry and academy. 
The present study describes the structural features of 5-substituted 
Indazole derivatives as inhibitors of GSK-3β and the predictive 
models to find relevant features of molecules by Quantitative 
Structure–Activity Relationships (QSAR) and Molecular docking. 
QSAR is being applied across various domains to know the structural 
features of small molecules. Molecular docking studies are 
constantly used to realize the ligand and receptor interaction. The 5-
substituted indazole are potent kinase inhibitors [1]. 2D/3D QSAR 
and docking studies are performed on 5-substitued-1H-indazole 
derivatives to get the insight about necessary structural features to 
optimize ligand to enhance biological activities. Based on significant 
2D/3D QSAR models, the Indazole derivatives were optimized and 
the effectiveness of optimized compounds towards GSK-3β were 
validated by using molecular docking studies. 
MATERIALS AND METHODS 
Dataset 
In this study, a series of 42 molecules belongs to GSK-3β inhibitors 
and their binding affinity (Ki in μM) were taken from the literature 
[1-2]. The compounds were sketched using ISIS draw. All molecules 
were optimized using Merck molecular force field MMFF as force 
field and charge. The inhibitors which had pKi as >5.00uM were 
considered as 5.00uM. The negative logarithm of the measured 
binding affinity [pKi = -log (Ki)] were considered as dependent 
variable for 2D/3D-QSAR analysis. The log pKi value ranges from 
5.26 to 8.00. The 5-substitued-1H-indazole derivatives listed in 
Table1. 
Selection of Training set and Test set 
The dataset of 42 molecules were divided into training set (34 
compounds) and test set (8 compounds) by sphere Exclusion 
Method. The various dissimilarity values were tried to get a desired 
division of training and test set. The accuracy of selection of test and 
training sets was confirmed by unicolumn statistics of test and 
training sets which is displayed in Table2. The maximum of the 
training set was more than that of the test set and the minimum of 
the training set was less than or equal to that of the test set. 
QSAR Modeling 
QSAR or quantitative structure–property relationships (QSPR) is a 
mathematical method to relate the set of compounds to its biological 
activity or property. QSAR study was applied using Vlife MDS 
software [14] to establish correlation between 2D/3D descriptors 
and experimental activity for set of compounds using statistical 
methods. 
A total of 252 descriptors like element counts, molecular weight, 
topological index, molecular refractivity, log P, Baumann alignment 
independent topological etc., were considered to generate 2D-QSAR 
model. The hydrophilic, steric and electrostatic field’s descriptors were 
calculated with default values of 30.0 and 10.0 kcal/mol as cutoff to 
generate significant 3D QSAR models. The activity field was considered 
as dependent variable and 2D/3D descriptors were considered as 
independent variables. The different QSAR models were generated by 
using multiple linear regression (MLR), principal component 
regression (PCR) and partial least squares (PLS) methods and variable 
selection methods like Forward–Backward stepwise, Genetic 
Algorithm and Simulated Annealing. 
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Table 1: Structure, experimental biological activities of 5-substitued-1H-indazole derivatives 
 
 
CPD  R1 R2 X/Y Ki (uM) 
1 CH3CH2CH2- - - 2.026 
2 CH3OCH2-  - - 5.450 
3 OH-CH2(CH2)2- - - 5.216 
4 C3H5- - - 3.466 
5 C5H9- - - 1.298 
6 C6H11-CH2- - - 0.891 
7* C6H5-CH2- - - 0.542 
8 C6H5-(CH2)2- - - 0.446 
9* C6H5-(CH2)3- - - 0.528 
10 H - - 0.448 
11* C6H5-CH2- - - 0.039 
12 C6H5-CH2- - X=NH2 0.265 
13* 2-Cl-C6H5-CH2- - - 0.045 
14 3-Cl-C6H5-CH2- - - 0.023 
15* 4-Cl-C6H5-CH2- - - 0.197 
16 2-F-C6H5-CH2- - - 0.091 
17 3-F-C6H5-CH2- - - 0.026 
18 4-F-C6H5-CH2- - - 0.070 
19 3-CH3-C6H5-CH2- - - 0.070 
20* 2-Cl,3-Cl-C6H5-CH2- - - 0.048 
21 3-Cl, 6-Cl-C6H5-CH2- - - 0.016 
22 3-Cl, 5-Cl-C6H5-CH2- - - 0.028 
23 C6H5-CH2- - X=H 0.572 
24 C6H5-CH2- - X=NH2 0.450 
25 CH3-(CH2)2- - X=H 2.530 
26 CH3-NHC(O)- - X=H 4.272 
27 PIPERIDINE-1-YL-CH2- - X=H 3.810 
28  H - - 0.141 
29  C6H5- - - 0.010 
30  H CH3 - 2.861 
31  H NH2 - 4.472 
32 C6H11- - X=C; Y=C 2.611 
33 C6H11- - Y=C; X=N 0.010 
34* (CH3)2-CH- - Y=C; X=N 0.017 
35 CH3-(CH2)3- - Y=C; X=N 0.019 
36 4-Cl-C6H5- - Y=C; X=N 0.121 
37 C6H11- - - 0.642 
38 (CH3)2N-(CH2)2- - - 5.450 
39  H CH3CH2NH- - 3.925 
40  H C6H5-NH- - 0.289 
41  C6H6- C6H5-NH- - 5.450 
42*  C6H6- C6H5-CH2-NH- - 3.402 
*Test set 
 
Table 2: Unicolumn statistics of training and test sets 
Set Average Max Min Std dev. Sum 
2D QSAR 
Training 6.3659 8.0000 5.2640 0.9251 216.4410 
Test 6.8202 7.7700 5.4680 0.7763 54.5620 
3D QSAR 
Training 6.4551 8.0000 5.2640 0.8816 200.1090 
Test 6.4449 8.0000 5.2640 1.0238 70.8940 
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For 2D-QSAR, all 42 molecules of 5-substituted-1H-indazole 
derivatives were subjected to regression analysis using MLR, PCR, 
and PLS as model building methods. 3D-QSAR models were 
generated using k-nearest neighbour (kNN) principle with stepwise, 
genetic algorithm and simulated annealing methods. 
The statistical parameters, n (number of compounds in regression), 
r2(coefficient of determination),k (number of descriptors in a 
model), F (F-test), pred_r2 (cross-validated correlation coefficients), 
pred_r2se (coefficient of correlation of predicted data set), r2_se and 
q2
Alignment 
_se were used to evaluate generated QSAR models. The developed 
QSAR models were validated by using external validation method. 
Molecular alignment is a key step to develop various reliable 3D-
QSAR models. 42 molecules were aligned by template based 
technique. The common structure 1H-Indazole was used as 
template. The aligned structures were used for 3D-QSAR study. A 
common rectangular grid was generated around the aligned 
molecules. The alignment of all molecules is shown in the Figure 1. 
 
Fig. 1: Molecules alignment of 5-substituted-1H-indazole 
derivatives 
Molecular docking 
Molecular docking was carried out to get better insight about 
interaction between protein and molecules. It is used to find 
energetically favourable conformation of ligand in the active site of 
protein. The protein coordinates of human GSK-3β (PDB ID: 1Q4L) 
was retrieved from Protein data bank (http: //www. pdb. org) and 
used as protein structure. Protein preparation steps includes 
removal of chain B and water molecules, cavity prediction, assigning 
bonds, bond order and hybridization, adding explicit hydrogen’s, 
assigning charges were done for chain A of 1Q4L by using Molgro 
Virtual Docker (MVD) trial version. MVD was used for docking as it is 
showed higher docking accuracy [13]. 
The binding cavities for chain A were found using cavity detection 
algorithm and the binding region was defined as X (39.83), Y (6.26), 
and Z (34.23) with a resolution of 0.30 Å and radius of 15 Å. The 
binding cavity volume (128.512 Å) was considered for docking 
studies. The reference ligand (679 from 1Q4L) was docked with 
MolDock Score [GRID], Mol Dock SE algorithm, number of runs was 
10 and max iterations was 1500, to validate the docking settings. 
The measured RMSD between docking simulation (yellow) and the 
original ligand (green) is 1.45Å with -150.491dockscore, -138.12 
interaction energy. Generally the docking method is considered as 
successful if the RMSD value is less than 2Å. The both ligand 679 and 
docking simulation ligand 679 interacted to the same residues 
Asp133, Val135, Arg141 and Gln185of 1Q4L Figure 2. The validated 
docking setting was used to perform docking calculation of Indazole 
derivatives. After docking, each pose of the ligands was manually 
analyzed to find best conformation based on interaction energy, 
interacting residues of ligand with the protein.  
 
Fig. 2: The ligand 679 (green) and docking simulation 
ligand679 (yellow) 
 
RESULTS AND DISCUSSION 
The 2D-QSAR significant models were generated using Multi linear 
regression, partial least square and principal component regression 
by forward-backward variable selection method. 
Model-1 (MLR) 
n = 34; Degree_of_freedom = 28; r2 = 0.8345; q2 = 0.7544; F_test = 
28.2363; r2_se = 0.4086; q2_se = 0.4977; pred_r2= 0.6887; pred_r2
pKi50 = + 0.0142(T_2_F_7) - 0.3144(Nitrogens Count) + 
0.2672(chi4) - 0.6610(T_N_N_5) + 1.8058(T_2_N_0) + 1.5853 
se = 
0.5109 
The Model 1 has correlation coefficient (r2) of 0.8345, significant 
cross validated correlation coefficient (q2) of 0.7544, F test of 
28.2363 and degree of freedom 28. The model is validated by 
best_ran_r2 = 0.42629, best_ran_q2 = 0.17788, Z score_ran_r2 = 
7.14878 and Z score_ran_q2
Model-2 (PLS) 
 = 5.70501. 
n = 34; Degree_of_freedom = 29; r2= 0.8818; q2 =0.7550; F_test= 
54.0711; r2_se = 0.3393; q2_se = 0.4884; pred_r2 = -0.0164; pred_r2
pKi50 = + 0.1772 (T_C_N_5) - 0.4006 (H-Acceptor Count) - 0.0000 
(Ipc Average) + 0.0964 (T_2_2_3) + 0.4953 (T_N_N_4) + 3.4710. 
se 
= 0.9232 
The Model 2 has correlation coefficient (r2) of 0.8818, significant 
cross validated correlation coefficient (q2) of 0.7550, F test of 
54.0711 and degree of freedom 29. The model is validated by 
best_ran_r2 = 0.41535, best_ran_q2 = 0.09836, Z score_ran_r2 = 
8.61461 and Z score_ran_q2
Model-3 (PCR) 
 = 4.76428. 
n = 34; Degree_of_freedom = 29; r2 = 0.8672; q2 = 0.8212; F_test = 
47.3469; r2_se = 0.3596; q2_se 0.4173; pred_r2
pKi50 = + 0.1347 (T_C_N_5) + 0.7747 (T_2_N_0) - 0.2878 (T_N_N_5) - 
0.0000 (Ipc) + 0.3184 (slogp) + 2.4170 
 =0.7102; pred_r2se = 
0.4072 
The Model 3 has correlation coefficient (r2) of 0.8672, significant 
cross validated correlation coefficient (q2) of 0.8212, F test of 
47.34 and degree of freedom 29. The model was validated by 
best_ran_r2 = 0.36941, best_ran_q2 = 0.13846, Z score_ran_r2 = 
9.25745 and Z score_ran_q2 = 7.36423. The statistically significant 
model-3 reveals that T_C_N_5 (25.50%) the number of carbon 
atoms (single, double or triple bonded) separated from nitrogen 
atom by 5 bond distance in a molecule (C-C-C-C-C-N), T_2_N_0 
Santhana et al. 
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(19.17%) is count of number of double bonded atoms (i. e., any 
double bonded atom, T_2) separated from nitrogen atoms by a 
zero bond distance and slogp (18.03%) descriptor signifies the 
Octanol/water partition coefficient. These descriptors are directly 
proportional to activity of molecules. T_N_N_5 and Ipc are 
negatively contribute towards biological activity. The plot of 
Actual vs. Predicted activity is shown in Figure 3. and predicted 






Fig. 3: (a) Graph of experimental versus predicted pKi (b) 
Contribution chart of descriptor for model 3 
The 3D-QSAR significant models were generated using k-nearest 
neighbour (kNN) principle with stepwise, genetic algorithm and 
simulated annealing methods. 
Model 4 
k Nearest Neighbour = 2; n = 34, Degree_of_freedom = 31; q2 = 
0.6051; q2_se = 0.5813; pred_r2 = 0.4966; pred_r2se = 0.6498; 
Selected Descriptors and range = E_484 (-1.4520, -1.2580) and 
H_312 (0.4730, 0.5620) 
pKi50 = E_484 (-1.4520, -1.2580) H_312 (0.4730, 0.5620) 
Model 4 describes that negative electrostatic potential (E_484) and 
hydrophobicity (H_312) determine the biological activity of 
compounds. 
Model 5 
k Nearest Neighbour = 5; n = 34, Degree_of_freedom = 30; q2 = 
0.4877; q2_se =0.6621; pred_r2 = 0.3794; pred_r2
In this model three descriptors hydrophobicity, positive and 
negative electrostatic potential has major contribution in inhibitory 
activity. 
Model 6 
k Nearest Neighbour = 2; n = 34, Degree_of_freedom = 28; q
se = 0.7214; 
Selected Descriptors and range = E_1030 (-1.8550, -1.5980), E_984 
(1.5100, 2.2200) and H_641 (0.1780, 0.3020) 
pKi50 = E_1030 (-1.8550, -1.5980) E_984 (1.5100, 2.2200) H_641 
(0.1780, 0.3020) 
2 
=0.7153; q2_se =0.4936; pred_r2 =0.2938; pred_r2se = 0.7696; 
Selected Descriptors and range = E_451 (1.9000, 1.9600), E_229 
(2.9320, 3.4120), S_914 (-0.0020 -0.0020), S_1080 (-0.0070, -
0.0060) and H_1052 (0.3500, 0.3830) 
pKi50 = E_451 (1.9000, 1.9600) E_229 (2.9320, 3.4120) S_914 (-
0.0020 -0.0020) S_1080 (-0.0070, -0.0060) H_1052 (0.3500, 0.3830) 
Model 6 found to be statistically significant with respect to external 
and internal predictive ability. The model showed internal 
predictive ability of about 70% (q2=0.7153) and external predictive 
ability of about 30 %(pred_r2
 
(a) 
=0.2938). This model explains the 
contributions of electrostatic (E_451, E_229) and hydrophobicity 
(H_1052) descriptors in the activity of 5-substituted Indazole based 
GSK-3β inhibitors. 
The plot of Actual vs. Predicted activity is shown in Figure 4. And the 
predicted pKi values are shown in Table3. 
 
(b) 
Fig. 4: (a) Graph of experimental versus predicted pKi (b) 
Important steric, electrostatic point contribution for model 6 
with values. 
 
In the present study, Model 3 from 2D QSAR and Model 6 from 3D-
QSAR were selected as best models based on r2, q2
The 14 molecules of 5-substituted-1H-indazole derivatives were 
selected for docking studies based on Ki values ranges from 0.01uM 
to 0.091uM and docking studies results were shown in the Table 4 
with MolDcok score, interacting residues, H-bond length for each 
molecule. In each docking run, the best poses were selected based on 
Moldock score and binding energy. 
. The 2D QSAR 
model explainsthatT_C_N_5, T_2_N_0 and slogp descriptors enhance 
the activity of compounds. In 3D QSAR, model 6 explains E_451, 
E_229 (electrostatic) and H_1052, (hydrophobicity) play vital roles 
in enhancing the activity of the compounds. These models were 
useful in optimizing the activity of 5-substituted Indazole analogs 
towards GSK-3β. 
Docking 
Santhana et al. 
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Table 3: Predicted values for statistically significant models 
S. No. Activity (PKi) Model-3Predicted Residue Model-6Predicted Residue 
1 5.693 5.63 0.06 5.68 0.01 
2 5.264 5.33 -0.06 5.40 -0.14 
3 5.283 5.30 -0.01 5.55 -0.27 
4 5.460 5.33 0.13 5.79 -0.33 
5 5.887 6.10 -0.21 5.58 0.30 
6 6.050 6.45 -0.40 6.35 -0.30 
7 6.266 6.28 -0.01 6.81 -0.54 
8 6.351 6.00 0.35 5.86 0.49 
9 6.277 5.88 0.39 6.94 -0.66 
10 6.349 6.25 0.10 6.20 0.15 
11 7.409 7.30 0.11 5.75 1.66 
12 6.577 7.39 -0.81 6.77 -0.19 
13 7.347 7.46 -0.11 6.75 0.60 
14 7.638 7.46 0.17 7.15 0.49 
15 6.706 7.46 -0.75 6.37 0.33 
16 7.041 7.29 -0.25 7.39 -0.35 
17 7.585 7.30 0.28 7.21 0.38 
18 7.155 7.30 -0.14 7.39 -0.24 
19 7.155 7.49 -0.33 6.47 0.68 
20 7.319 7.59 -0.27 7.35 -0.03 
21 7.796 7.59 0.20 6.64 1.16 
22 7.553 7.61 -0.06 7.11 0.44 
23 6.243 5.88 0.36 5.95 0.29 
24 6.347 5.97 0.38 6.20 0.15 
25 5.597 5.41 0.18 5.79 -0.19 
26 5.369 5.07 0.30 5.81 -0.44 
27 5.419 5.79 -0.37 6.29 -0.87 
28 6.851 6.97 -0.11 6.89 -0.04 
29 8.000 8.15 -0.15 7.89 0.11 
30 5.543 5.52 0.02 5.97 -0.42 
31 5.349 5.47 -0.12 5.36 -0.01 
32 5.583 6.27 -0.69 6.49 -0.90 
33 8.000 7.35 0.65 7.87 0.13 
34 7.770 7.58 0.19 8.00 -0.23 
35 7.721 7.57 0.15 7.41 0.31 
36 6.917 7.12 -0.20 6.99 -0.07 
37 6.192 6.52 -0.32 6.31 -0.12 
38 5.264 5.51 -0.25 5.84 -0.57 
39 5.406 5.46 -0.05 5.92 -0.51 
40 6.539 6.24 0.30 5.40 1.14 
41 5.264 4.98 0.28 6.09 -0.83 
42 5.468 3.29 2.18 5.83 -0.37 
 
The Table 4 indicates the reasonable Moldock score ranges from -
137.063 to -116.562 for stable interaction between ligand and protein. 
The highly active compounds of 29 and 33 resulted with highest 
docking score of -130.097 and -125.554,respectively. The results 
explain that the Indazole derivatives interact with Val135, Gln185, 
Asp200, and Arg141 residues in the active site through the nitrogen 
atom of cyclic ring substituted in the 5th position of Indazole 
derivatives is one of the crucial factors for more binding affinities. 
Figure 5a shows the binding image of compound 29 shows interaction 
energy -137.83 kcal/mol and -130.097 MolDock score forming 
favourable interaction with Val135 and Glu97 amino acids and Figure 
5b shows binding image of compound 33 shows interaction energy -
127.57 kcal/mol and -125.554 MolDock score forming favourable 
interactions with Val135 and Phe201 amino acids. 
 
Table 4: Docking result of experiment compounds 
Cpd. 
No 
Ki (uM) MolDock Score Interaction Energy Residue H-bond length 
11 0.039 -116.562 -128.59 Glu97, Cys199 3.11,3.25 
13 0.045 -118.013 -122.11 Val135, Asp200,Glu97 3.30,3.13,3.42 
14 0.023 -120.844 -133.79 Val135, Arg141, IIe62 (3.23,3.10),3.23, 3.14 
16 0.091 -117.417 -124.03 Val135 3.32 
17 0.026 -117.573 -120.00 Gln185, Tyr134,Val135 (3.04,3.16),3.05, 3.08 
18 0.07 -118.108 -118.70 Gln185, Tyr134, Pro136 3.16,2.97,2.84 
19 0.07 -125.66 -114.34 Gln185,Glu97, Cys199 (3.18,3.15),3.09,3.00 
20 0.048 -126.385 -130.92 Phe201, Glu97 3.48,3.01 
21 0.016 -125.964 -131.29 Gln185, Glu97 3.32,3.24 
22 0.028 -130.113 -115.25 Val135,Glu97,Phe201, Asp200 3.39,3.07,3.39, 3.20 
29 0.01 -130.097 -137.83 Val135, Glu97 3.28, 2.90 
33 0.01 -125.554 -127.57 Val135, Phe 201 2.84, 3.15 
34 0.017 -131.935 -98.58 Val135, Glu97 3.09, 2.82 
35 0.019 -137.063 -106.53 Val135, Asp200 2.90, 3.36 
Santhana et al. 




(a)     (b) 
Fig. 5: Hydrogen bond interaction between (a) compound 29 and (b) compound 33 with receptor 
 
Based on QSAR Models (3&6) 450 new compounds were designed 
by substituting various substituents (methyl; ethyl; n-propyl; 
hydrogen; amino; hydroxy; acetyl amino; 1H-imidazol-4-yl; 
cyclohexylamino; pyrimidine-4-yl; 6-oxo-2-piperidyl and 3-OH-
pyridin-4-yl) in skeleton structures which are shown in Table1. The 
docking of GSK-3β (1Q4L) receptor with all newly designed ligands 
exhibited well established bonds with amino acids in the receptor’s 
active pocket. Most of the compounds showed better interaction 
energy and MolDock Score than experimental compounds. Figure 6a 
shows docking images of compound Id 416 shows interaction 
energy of -139.58 kcal/mol and MolDock score of -148.49 having 
interaction with Val135, Gln185 and Asp200 and Figure 6b shows 
docking images of compound Id 397 shows interaction energy of -
120.99 kcal/mol and -145.29 having interactions with 
Val135,Gln185 and Asp200 
Based on the docking score and interaction energy, best 31 
compounds were selected and listed in Table 5 and their docking 
score, interaction energy, interacting residues and H-bond distance 
were reported in Table 6. Docking studies reveal that 31 optimized 
ligands showed good binding with favourable hydrogen bond 
interaction toward GSK-3β. Optimized scaffold OPT5 derivatives 





(a)      (b) 
Fig. 6: Hydrogen bond interaction compounds (a) Cpd_ID 416 and (b)Cpd_ID397with receptor 
 
Table 5: Newly designed compounds 
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Cpd_ID Core R1 R2 R3 R4 R5 
416 OPT1 n-propyl 6-oxo-2-piperidyl H H - 
397 OPT1 ethyl 6-oxo-2-piperidyl H H - 
308 OPT3 n-propyl pyrimidine-4-yl H H - 
46 OPT4 n-propyl H 3-OH-pyridin-4-yl H H 
107 OPT4 H 3-OH-pyridin-4-yl H H H 
468 OPT2 n-propyl H 6-oxo-2-piperidyl - - 
282 OPT3 H 1H-imidazol-4-yl H H - 
453 OPT1 n-propyl H 3-OH-pyridin-4-yl H - 
141 OPT5 H Pyrimidine-4-yl H H H 
435 OPT1 ethyl H 6-oxo-2-piperidyl H - 
134 OPT4 ethyl 6-oxo-2-piperidyl H H H 
434 OPT1 ethyl H 3-OH-pyridin-4-yl H - 
126 OPT4 methyl 3-OH-pyridin-4-yl H H H 
118 OPT4 n-propyl 1H-imidazol-4-yl H H H 
71 OPT4 H H H 6-oxo-2-piperidyl H 
68 OPT4 H H H acetylamino H 
139 OPT5 H acetylamino H H H 
514 OPT2 ethyl 3-OH-pyridin-4-yl H - - 
78 OPT4 n-propyl H H cyclohexylamino  
471 OPT2 n-propyl H cyclohexylamino - - 
36 OPT4 H H 6-oxo-2-piperidyl H H 
160 OPT5 methyl 6-oxo-2-piperidyl H H H 
210 OPT5 H H H acetylamino H 
161 OPT5 methyl 3-OH-pyridin-4-yl H H H 
152 OPT5 n-propyl 3-OH-pyridin-4-yl H H H 
108 OPT4 H 1H-imidazol-4-yl H H H 
456 OPT1 n-propyl H pyrimidine-4-yl H - 
100 OPT4 ethyl H H 1H-imidazol-4-yl H 
347 OPT3 n-propyl H 6-oxo-2-piperidyl H - 
55 OPT4 methyl H 3-OH-pyridin-4-yl H H 
10 OPT2 ethyl 6-oxo-2-piperidyl H - - 
 
Table 6: Docking results of newly designed compounds 
Cpd_ID MolDock Score Interaction Energy Residue Hbond length 
416 -148.49 -139.58 Val135,Gln185,Asp200 3.31,2.91,3.16 
397 -145.29 -120.99 Val135,Gln185,Asp200 3.13,2.84,3.17 
308 -148.36 -126.58 Asp200,Val135 3.00, 3.22 
46 -142.55 -145.89 Val135,Gln185,Asp200,Tyr134, Lys85 2.99,2.94,3.41,3.09,3.22 
107 -140.87 -141.58 Val135,Gln185,Asp200, Phe201,Glu97 3.15,2.79,3.23,3.21,2.70 
468 -140.67 -134.78 Val135,Gln185,Asp200 3.10,2.61,3.22 
282 -139.96 -124.90 Asp133,Gln185 2.93,2.62,(3.20,3.43) 
453 -139.40 -143.90 Arg141,Val135,Asp200 2.77,(3.13,2.63),(3.22,3.19) 
141 -138.78 -141.48 Val135,Gln185,Cys199,Glu97, Phe201 3.10,2.90,2.81,2.56,3.39 
435 -137.07 -137.88 Val135,Tyr134,Asp200 (3.30,2.94),2.76,(3.15,3.16) 
134 -136.38 -139.93 Val135,Gln185,Asp200 3.16,3.09, (3.28,3.23) 
434 -136.01 -138.50 Val135,Arg141,Asp200 (3.15,2.63),2.81,(3.15, 3.16) 
126 -135.65 -134.85 Val135,Gln185,Asp200, Phe201 3.29,2.92,3.21,3.39 
118 -135.32 -127.54 Val135,Gln185,Asp200,Lys85 2.62,3.07,3.14,2.94 
71 -134.52 -142.18 Val135,Arg141,Asp200,Phe201, Glu97 3.28,3.24,3.20,3.29,2.73 
68 -134.34 -135.16 Val135,Arg141,Asp200,Phe201, Glu97 3.20,3.24,3.24,3.34,2.73 
139 -134.17 -130.92 Val135,Gln185,Glu97 3.09,2.92,2.58 
514 -134.00 -136.02 Val135,Arg141,Asp200 (2.63,3.20),3.25,(3.17,319) 
78 -133.62 -136.57 Val135,Arg141 3.29,(2.98,3.30) 
471 -133.46 -125.39 Val135,Gln185 3.22,(2.90,3.06) 
36 -133.12 -138.32 Val135,Arg141,Glu97 3.38,2.91, 2.93 
160 -133.04 -134.64 Val135,Gln185,Asp200 2.90,3.17, (3.13, 3.32) 
210 -132.22 -133.96 Val135,Arg141,Glu97 3.24,3.26, 2.71 
161 -132.10 -129.92 Val135,Gln185,Asp200,Cys199 3.23,3.10, 3.38, 2.59 
152 -132.09 -136.18 Val135,Asp133,Gln185, Asp200 3.02,2.80,3.29, 3.19 
456 -131.77 -141.36 Val135, Arg141, Asp200 3.12,2.98, 3.11 
100 -131.72 -131.07 Val135, Asp200, Lys85 3.07,3.07, 3.42 
347 -131.68 -127.52 Val135, Arg141 3.39,(3.05,3.08) 
55 -131.63 -135.45 Val135, Arg141, Asp200 3.21,3.31,(3.15,3.27) 
10 -131.21 -134.35 Val135, Asp200, Tyr134 3.16, (3.13, 3.096), 3.18 
108 -131.84 -126.01 Asn 64,Asp133,Asp200,Phe 201 3.07,2.59,(3.14,3.06,3.11), 3.55  
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In present study 2D/3D QSAR and docking studies on series of 
Indazole derivatives were applied successfully to identify the 
necessary structural, substituent requirements and potential 
interaction of 5-subsituted Indazole derivatives of GSK-3β inhibitors. 
2D-QSAR descriptors T_C_N_5, T_2_N_0, slogp descriptors and 3D-
QSAR descriptors E_451, E_229 (electrostatic) and H_1052, 
(hydrophobicity) enhance the binding affinities of compounds. 
Docking study showed the important interacting residues in the 
active site of receptor are Val135, Gln185, Arg141 and Asp 200 with 
ligands. Optimized 31 ligands have good docking score and 
favourable interactions in the active site. These compounds seem to 
be having more binding affinities towards GSK-3β. As per our 
knowledge these compounds have not been reported as potential 
inhibitors so far. Therefore, the optimized molecules could be new 
potential candidates as GSK-3β inhibitors. 
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